Research view
Switch to patient viewAcute myeloid leukaemia: trials that stopped early
Trials on Acute myeloid leukaemia that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.
Stopped early
167 stopped trials give a reason in the registry, latest registry update first. 4 more give no reason and are not listed.
Withdrawn
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Reason given in the registry “Change in Study Design”
Quoted unchanged from ClinicalTrials.gov; record updated 24 Feb 2026.
- Ended
- Nov 2024
- Phase
- Phase 1
- Run by
- Ossium Health, Inc.
- Registry record
- NCT05170828
Terminated
Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia
Reason given in the registry “Sponsor decision”
Quoted unchanged from ClinicalTrials.gov; record updated 23 Feb 2026.
- Ended
- Oct 2025
- Phase
- Phase 1
- Run by
- Brian Jonas
- Registry record
- NCT04964505
Terminated
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
Reason given in the registry “The study was terminated based on strategic evaluation of the clinical development of HMPL-306 with no safety concerns”
Quoted unchanged from ClinicalTrials.gov; record updated 29 Jan 2026.
- Ended
- Jan 2025
- Phase
- Phase 1
- Run by
- Hutchmed
- Registry record
- NCT04764474
Terminated
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
Reason given in the registry “As a result of program reprioritization and due to the limited clinical activity observed in the Phase 1 trial, the study has been discontinued.”
Quoted unchanged from ClinicalTrials.gov; record updated 28 Jan 2026.
- Ended
- Jan 2025
- Phase
- Phase 1
- Run by
- NextCure, Inc.
- Registry record
- NCT05787496
Terminated
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Reason given in the registry “The data met the protocol-specified criteria for futility of the investigational treatment.”
Quoted unchanged from ClinicalTrials.gov; record updated 22 Jan 2026.
- Ended
- Jan 2026
- Phase
- Phase 3
- Run by
- Delta-Fly Pharma, Inc.
- Registry record
- NCT03926624
Terminated
A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy
Reason given in the registry “Novartis made a decision to early terminate the sabatolimab clinical development program, including the CMBG453C12201 trial, following the negative results from other 2 trials.”
Quoted unchanged from ClinicalTrials.gov; record updated 13 Jan 2026.
- Ended
- Oct 2024
- Phase
- Phase 2
- Run by
- Novartis Pharmaceuticals
- Registry record
- NCT04150029
Terminated
Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant
Reason given in the registry “Study was terminated early due to lack of accrual and loss of funding.”
Quoted unchanged from ClinicalTrials.gov; record updated 9 Jan 2026.
- Ended
- Sept 2024
- Phase
- Phase 2
- Run by
- Sanjay Mohan
- Registry record
- NCT05799079
Terminated
Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients
Reason given in the registry “business/strategic reason”
Quoted unchanged from ClinicalTrials.gov; record updated 26 Dec 2025.
- Ended
- Aug 2025
- Phase
- Phase 1/2
- Run by
- JW Pharmaceutical
- Registry record
- NCT03055286
Terminated
Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients
Reason given in the registry “The research center has conducted a more comprehensive study.”
Quoted unchanged from ClinicalTrials.gov; record updated 5 Dec 2025.
- Ended
- Jan 2024
- Phase
- Phase 2
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
- Registry record
- NCT05361057
Terminated
Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes
Reason given in the registry “Drug company withdrew support.”
Quoted unchanged from ClinicalTrials.gov; record updated 2 Dec 2025.
- Ended
- Mar 2025
- Phase
- Phase 1/2
- Run by
- National Cancer Institute (NCI)
- Registry record
- NCT05918055
Suspended
A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid Leukemia
Reason given in the registry “Product manufacturing process improvement”
Quoted unchanged from ClinicalTrials.gov; record updated 24 Nov 2025.
- Ended
- Aug 2026
- Phase
- Phase 1
- Run by
- He Huang
- Registry record
- NCT06709131
Terminated
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies
Reason given in the registry “Slow enrolment”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Nov 2025.
- Ended
- Oct 2025
- Phase
- Phase 1
- Run by
- Kahr Medical
- Registry record
- NCT04937166
Terminated
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
Reason given in the registry “The study terminated early because the company was longer providing the investigational product.”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Nov 2025.
- Ended
- Sept 2024
- Phase
- Phase 1/2
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT04874194
Terminated
Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant
Reason given in the registry “Despite a plan to enroll \~195-210 participants, the ARTEMIS study was closed due to the long vein-to-vein manufacturing timeline of MT-401 after 38 participants received the autologous MT-401.”
Quoted unchanged from ClinicalTrials.gov; record updated 30 Oct 2025.
- Ended
- Mar 2024
- Phase
- Phase 2
- Run by
- Marker Therapeutics, Inc.
- Registry record
- NCT04511130
Terminated
Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.
Reason given in the registry “Study was stopped following a strategic decision from the Sponsor. It was not based on any safety findings or safety concerns with sabatolimab.”
Quoted unchanged from ClinicalTrials.gov; record updated 16 Oct 2025.
- Ended
- Aug 2024
- Phase
- Phase 1/2
- Run by
- Novartis Pharmaceuticals
- Registry record
- NCT04623216
Terminated
CD123 Redirected T Cells for AML in Pediatric Subjects
Reason given in the registry “Administrative reasons”
Quoted unchanged from ClinicalTrials.gov; record updated 15 Oct 2025.
- Ended
- May 2025
- Phase
- Phase 1
- Run by
- University of Pennsylvania
- Registry record
- NCT04678336
Terminated
VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)
Reason given in the registry “Business reasons”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Oct 2025.
- Ended
- Jul 2024
- Phase
- Phase 1
- Run by
- Novartis Pharmaceuticals
- Registry record
- NCT04702425
Terminated
HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
Reason given in the registry “Business decision”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Oct 2025.
- Ended
- Aug 2024
- Phase
- Phase 1
- Run by
- Novartis Pharmaceuticals
- Registry record
- NCT03940352
Terminated
ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)
Reason given in the registry “The Trial was early terminated due to deficiencies in the Achieve Protocol: V8.0 dated 19 January 2024.”
Quoted unchanged from ClinicalTrials.gov; record updated 30 Sept 2025.
- Ended
- Jul 2025
- Phase
- Phase 2
- Run by
- TC Biopharm
- Registry record
- NCT05358808
Terminated
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
Reason given in the registry “Lack of Funding”
Quoted unchanged from ClinicalTrials.gov; record updated 29 Jul 2025.
- Ended
- May 2025
- Phase
- Phase 1/2
- Run by
- Vor Biopharma
- Registry record
- NCT04849910
Terminated
Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant
Reason given in the registry “Lack of Funding”
Quoted unchanged from ClinicalTrials.gov; record updated 29 Jul 2025.
- Ended
- May 2025
- Phase
- Phase 1/2
- Run by
- Vor Biopharma
- Registry record
- NCT05984199
Terminated
A Long-term Follow-up Study of Patients Who Received VOR33
Reason given in the registry “Lack of Funding”
Quoted unchanged from ClinicalTrials.gov; record updated 29 Jul 2025.
- Ended
- May 2025
- Run by
- Vor Biopharma
- Registry record
- NCT05309733
Withdrawn
TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant
Reason given in the registry “No funding available.”
Quoted unchanged from ClinicalTrials.gov; record updated 14 Jul 2025.
- Run by
- Neena Kapoor, M.D.
- Registry record
- NCT05968170
Terminated
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
Reason given in the registry “sponsor decision, unrelated to safety”
Quoted unchanged from ClinicalTrials.gov; record updated 9 Jul 2025.
- Ended
- May 2024
- Phase
- Phase 1
- Run by
- Amgen
- Registry record
- NCT02675452
Terminated
Connect® Myeloid Disease Registry
Reason given in the registry “Business objectives have changed”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Jul 2025.
- Ended
- Oct 2024
- Run by
- Celgene
- Registry record
- NCT01688011
Terminated
Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML
Reason given in the registry “In light of the strategic realignment of the company's development focus, it has been determined to discontinue the further development of Uproleselan Injection.”
Quoted unchanged from ClinicalTrials.gov; record updated 27 Jun 2025.
- Ended
- Aug 2024
- Phase
- Phase 3
- Run by
- Apollomics Inc.
- Registry record
- NCT05054543
Terminated
CART-38 in Adult AML and MM Patients
Reason given in the registry “Administrative decision”
Quoted unchanged from ClinicalTrials.gov; record updated 26 Jun 2025.
- Ended
- Feb 2025
- Phase
- Phase 1
- Run by
- University of Pennsylvania
- Registry record
- NCT05442580
Withdrawn
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias
Reason given in the registry “Business Decision”
Quoted unchanged from ClinicalTrials.gov; record updated 22 Jun 2025.
- Phase
- Phase 1
- Run by
- Janssen Research & Development, LLC
- Registry record
- NCT05521087
Terminated
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Reason given in the registry “Trial terminated because of lack of efficacy in the short term acute phase.”
Quoted unchanged from ClinicalTrials.gov; record updated 12 Jun 2025.
- Ended
- Apr 2024
- Phase
- Phase 1
- Run by
- Celgene
- Registry record
- NCT02848001
Withdrawn
Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia
Reason given in the registry “no patients”
Quoted unchanged from ClinicalTrials.gov; record updated 11 Jun 2025.
- Ended
- Dec 2023
- Phase
- Phase 1
- Run by
- Beijing Boren Hospital
- Registry record
- NCT05248685
Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.